Ken Griffin Codiak Bio Sciences, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.18 - $0.81 $612 - $2,754
-3,400 Reduced 82.93%
700 $0
Q4 2022

Feb 14, 2023
SELL
$0.32 - $0.9 $2,912 - $8,190
-9,100 Reduced 68.94%
4,100 $1,000
Q3 2022

Nov 14, 2022
BUY
$0.82 - $3.19 $2,132 - $8,294
2,600 Added 24.53%
13,200 $10,000

Others Institutions Holding CDAK

# of Institutions
1
Shares Held
238K
Call Options Held
0
Put Options Held
0
View Full List

About Codiak BioSciences, Inc.

CDAK Quotes by TradingView
  • Ticker CDAK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,995,200
  • Market Cap $360K
  • Description
  • Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...
More about CDAK
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email